Paper · 11745189

The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas.

Kimura T and 5 others. Cancer, 2001. Cited by 71 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Papers, record 11745189. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11745189

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas.; PubMed
Journal: Cancer; PubMed
Year: 2001; PubMed
Publication types: Journal Article; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/11745189/; PubMed
DOI: https://doi.org/10.1002/1097-0142(20011115)92:10<2555::aid-cncr1607>3.0.co;2-m; PubMed
The journal: https://conductscience.org/library/journal-index/0374236; PubMed
Citations, by iCite: 71; iCite
Relative citation ratio, by iCite: 1.29; iCite
Revised in PubMed: 2022-03-16; PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Kimura T	T
2	Suzuki H	H
3	Ohashi T	T
4	Asano K	K
5	Kiyota H	H
6	Eto Y	Y

Source PubMed

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Carcinoma, Transitional Cell	Major topic
Point Mutation	Major topic
Protein-Tyrosine Kinases	Major topic
Receptors, Fibroblast Growth Factor	Major topic
Thanatophoric Dysplasia	Major topic
Urinary Bladder Neoplasms	Major topic
Adult
Aged
Aged, 80 and over
Cell Transformation, Neoplastic
Disease Progression
Female
Humans
Male
Middle Aged
Neoplasm Staging
Polymerase Chain Reaction
Polymorphism, Restriction Fragment Length
Polymorphism, Single-Stranded Conformational
Receptor, Fibroblast Growth Factor, Type 3
Sequence Analysis, DNA

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by27

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 71 citations.

PMID	Title	Journal	Year	In Papers	Source
40,762,043	Treatment strategies for locally advanced and metastatic urothelial carcinoma based on molecular profiles: A Review.	Histol Histopathol	2026	https://conductscience.org/library/papers/40762043	PubMed
38,994,535	Spectrum of FGFR2/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma.	Bladder Cancer	2021	https://conductscience.org/library/papers/38994535	PubMed
35,501,832	Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.	BMC Cancer	2022	https://conductscience.org/library/papers/35501832	PubMed
35,406,567	Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer.	Cancers (Basel)	2022	https://conductscience.org/library/papers/35406567	PubMed
32,724,417	MKP-1 overexpression is associated with chemoresistance in bladder cancer via the MAPK pathway.	Oncol Lett	2020	https://conductscience.org/library/papers/32724417	PubMed
32,721,083	Molecular investigation of FGFR3 gene mutation and its correlation with clinicopathological findings in Indian bladder cancer patients.	Cancer Rep (Hoboken)	2018	https://conductscience.org/library/papers/32721083	PubMed
29,615,843	Bioinformatic analysis of prognostic value of ZW10 interacting protein in lung cancer.	Onco Targets Ther	2018	https://conductscience.org/library/papers/29615843	PubMed
28,589,387	Non-invasive papillary urothelial carcinoma of the vagina: molecular analysis of a rare case identifies clonal relationship to non-invasive urothelial carcinoma of the bladder.	Virchows Arch	2017	https://conductscience.org/library/papers/28589387	PubMed
27,930,669	Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples.	PLoS One	2016	https://conductscience.org/library/papers/27930669	PubMed
27,381,494	A place for precision medicine in bladder cancer: targeting the FGFRs.	Future Oncol	2016	https://conductscience.org/library/papers/27381494	PubMed

1 to 10 of 27

See all 27 cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes
FGFR3	2,261	PubTator's text mining	https://conductscience.org/library/genes/2261

Source NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/11745189

GET https://conductscience.org/api/papers/v1/11745189/cited_by?page=2

API reference For AI assistants